• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Teva Pharmaceutical Industries Limited

    9/12/25 4:05:13 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TEVA alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001166309
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Teva Pharmaceutical Industries Limited
    SEC File Number
    001-16174
    Address of Issuer
    124 Dvora HaNevi'a St
    Tel Aviv
    ISRAEL
    6944020
    Phone
    972-3-914-8213
    Name of Person for Whose Account the Securities are To Be Sold
    Bridger Management, LLC (1)
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Shareholder

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    American Depositary Shares
    Piper Sandler & Co.
    1 Greenwich Plaza
    Greenwich � CT � 06830
    950001889550.00114715091709/12/2025
    NYSE


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    American Depositary Shares05/09/2018See Remark 2See Remark 2Checkbox not checked9500005/09/2018See Remark 2

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    (1) Bridger Management, LLC ("Bridger") serves as the investment manager of Swiftcurrent Master Fund, Ltd., which holds the American Depositary Shares ("ADSs") representing Ordinary Shares covered by this Form 144. Roberto Mignone, Founder and Managing Partner of Bridger, is a member of the board of directors of the Issuer. (2) The ADSs reported herein to be sold were originally acquired through open market purchases on dates ranging from May 9, 2018 to May 10, 2018.
    Date of Notice
    09/12/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    Bridger Management, LLC, By: /s/ Matthew P. Truax, Chief Operating Officer, General Counsel and Chief Compliance Officer

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $TEVA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TEVA

    DatePrice TargetRatingAnalyst
    6/6/2025$24.00Buy
    Goldman
    5/28/2025$25.00Buy
    Truist
    5/12/2025$23.00Neutral → Overweight
    Analyst
    7/10/2024$20.00Hold → Buy
    Argus
    3/8/2024$14.00Underweight → Neutral
    JP Morgan
    2/12/2024$12.00 → $19.00Neutral → Overweight
    Piper Sandler
    1/23/2024$10.00 → $14.00Hold → Buy
    Jefferies
    1/3/2024$8.00 → $12.00Underweight → Neutral
    Piper Sandler
    More analyst ratings

    $TEVA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction

    Of the 209 patients with tardive dyskinesia (TD) that were surveyed, >94% reported movement improvement once treated with AUSTEDO XR® (deutetrabenazine) extended-release tabletsPatients reported high satisfaction (>89%) with AUSTEDO XR, with 96% expressing interest in continuing treatmentAlmost all (>96%) patients relayed that AUSTEDO XR was easy to take PARSIPPANY, N.J. and TEL AVIV, Israel, Sept. 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of data from a real-world survey of patients taking AUSTEDO XR® (deutetrabenazine) extended-release tablets. Patients taking AUST

    9/20/25 10:16:00 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

    Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) events observed with olanzapine LAI (TEV-'749) and its long-term systemic safety profile was consistent with other olanzapine formulations1Additional new data comparing initiation of UZEDY® (risperidone) versus Invega Sustenna® (paliperidone palmitate) in hospitalized patients found that UZEDY was associated with shorter length of stay and was preferred overall by HCPs due to its dosing characteristics and ease of use1Teva is committed to researching and developing innovative medicines that help address unmet needs for individuals living with complex mental health condi

    9/20/25 10:15:00 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-'749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting

    TEL AVIV, Israel, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced plans to present data from the completed phase 3 SOLARIS trial at the 2025 Psych Congress Annual Meeting, taking place from September 17 – 21, 2025, in San Diego, California. Teva will also host a conference call for analysts and investors on Monday, September 22, 2025, at 11:00 a.m. ET to discuss these data. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. To access a live webcast of the presentation, visit Teva's Investor Relations website at https://ir.tev

    9/16/25 4:30:00 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TEVA
    SEC Filings

    View All

    SEC Form 144 filed by Teva Pharmaceutical Industries Limited

    144 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Subject)

    9/12/25 4:05:13 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Teva Pharmaceutical Industries Limited

    SCHEDULE 13G/A - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Subject)

    8/6/25 12:14:18 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Teva Pharmaceutical Industries Limited

    10-Q - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Filer)

    7/30/25 4:06:44 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TEVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman initiated coverage on Teva Pharma with a new price target

    Goldman initiated coverage of Teva Pharma with a rating of Buy and set a new price target of $24.00

    6/6/25 8:33:51 AM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist initiated coverage on Teva Pharma with a new price target

    Truist initiated coverage of Teva Pharma with a rating of Buy and set a new price target of $25.00

    5/28/25 9:09:46 AM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Teva Pharma upgraded by Analyst with a new price target

    Analyst upgraded Teva Pharma from Neutral to Overweight and set a new price target of $23.00

    5/12/25 8:18:58 AM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TEVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Chief Legal Officer Mcavoy David R. bought $20,988 worth of Ordinary Shares (1,113 units at $18.86), increasing direct ownership by 9% to 13,027 units (SEC Form 4)

    4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)

    9/9/25 4:02:56 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    See "Remarks" Jover Placid converted options into 12,827 units of Ordinary Shares and sold $91,748 worth of Ordinary Shares (6,053 units at $15.16) (SEC Form 4)

    4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)

    8/5/25 4:04:57 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    See "Remarks" Hughes Eric A converted options into 52,742 units of Ordinary Shares and sold $799,437 worth of Ordinary Shares (52,742 units at $15.16) (SEC Form 4)

    4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)

    8/5/25 4:02:24 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TEVA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Chief Legal Officer Mcavoy David R. bought $20,988 worth of Ordinary Shares (1,113 units at $18.86), increasing direct ownership by 9% to 13,027 units (SEC Form 4)

    4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)

    9/9/25 4:02:56 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TEVA
    Leadership Updates

    Live Leadership Updates

    View All

    The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?

    USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 26, 2025 /PRNewswire/ -- USA News Group News Commentary – With analysts forecasting the global oncology drug market to surpass US$900 billion by 2034, investor interest in cancer-focused biotechs is rapidly intensifying. ResearchAndMarkets and Vision Research Reports both point to strong double-digit growth, citing surging demand for next-gen diagnostics and immunotherapies. Yet even as market potential grows, the U.S. public health sector is facing potential setbacks. Budget proposals suggest National Cancer Institute (NCI) funding could be slashed by up to 40%, while Bloomberg highlights concerns 

    6/26/25 11:44:00 AM ET
    $ADCT
    $CTOR
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Matthew Shields as Executive Vice President of Teva Global Operations (TGO), the Company's manufacturing and supply division, effective June 3, 2024. Mr. Shields succeeds Eric Drapé, who is leaving after 11 years with the Company, including more than four years as Executive Vice President, Global Operations. Mr. Shields will be a member of Teva's Executive Leadership Team and report directly to President and CEO Richard Francis. He will be based in Teva's U.S. headquarters in Parsippany, NJ. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2

    5/15/24 8:15:00 AM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Teva appoints new CEO for Teva api, its Active Pharmaceutical Ingredients Business

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Dr. R. Ananthanarayanan (Ananth) as CEO of its Teva Active Pharmaceutical Ingredients business (Teva api). Dr. Ananth will lead the API business starting November 27, 2023, and will be based out of Teva's U.S. headquarters in Parsippany, NJ. Richard Francis, Teva's President and CEO said: "I am excited to welcome Ananth back to Teva to lead the Teva api business during this pivotal time for our company, as we continue to progress on our plan for turning Teva api into a standalone business. We're confident that this strategy will result in a more focused end-to-end operation, and I am confident tha

    11/7/23 4:30:00 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TEVA
    Financials

    Live finance-specific insights

    View All

    New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

    Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) events observed with olanzapine LAI (TEV-'749) and its long-term systemic safety profile was consistent with other olanzapine formulations1Additional new data comparing initiation of UZEDY® (risperidone) versus Invega Sustenna® (paliperidone palmitate) in hospitalized patients found that UZEDY was associated with shorter length of stay and was preferred overall by HCPs due to its dosing characteristics and ease of use1Teva is committed to researching and developing innovative medicines that help address unmet needs for individuals living with complex mental health condi

    9/20/25 10:15:00 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-'749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting

    TEL AVIV, Israel, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced plans to present data from the completed phase 3 SOLARIS trial at the 2025 Psych Congress Annual Meeting, taking place from September 17 – 21, 2025, in San Diego, California. Teva will also host a conference call for analysts and investors on Monday, September 22, 2025, at 11:00 a.m. ET to discuss these data. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. To access a live webcast of the presentation, visit Teva's Investor Relations website at https://ir.tev

    9/16/25 4:30:00 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components

    On track for 30% operating profit margin by 2027 in line with our Pivot to Growth Strategy.Q2 2025 shows 10th consecutive quarter of year-over-year (YoY) revenue growth; Revenues of $4.2 billion, +1% in local currencyterms ("LC")excluding Japan BV revenues; United States segment +2%; Europe segment +3% in LC; International Markets segment -4% inLCand excluding Japan BV revenues. Innovative portfolio continues to fuel strong growth and provide value to diverse and critical patient populations: AUSTEDO® – shows continued strong growth with global revenues of $498 million in Q2 2025, +19% in LC compared to Q2 2024; U.S. revenues +22% compared to Q2 2024. Increasing 2025 revenue outlook to $

    7/30/25 7:00:00 AM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TEVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Teva Pharmaceutical Industries Limited

    SC 13G - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Subject)

    11/12/24 10:34:14 AM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Teva Pharmaceutical Industries Limited (Amendment)

    SC 13G/A - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Subject)

    4/9/24 10:26:26 AM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Teva Pharmaceutical Industries Limited

    SC 13G - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Subject)

    2/1/24 8:03:56 AM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care